Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has uploaded the audio recording of its conference call discussing results for the quarter ended June 30, 2026. The call took place on August 5, 2026, and the recording is now available on the company’s website for investor access. This disclosure ensures transparency regarding management’s commentary on financial performance and operational updates for Q4FY26.

The upload was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action follows the initial intimation of the conference call results dated July 23, 2026. The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) of the availability of the recording.

Key Details

Sisir Kumar Mishra, Company Secretary & Compliance Officer, signed the disclosure. The communication was addressed to the BSE at Dalal Street, Mumbai, and the NSE at Bandra Kurla Complex, Mumbai. The recording provides stakeholders with direct access to the dialogue between management and analysts, offering clarity on the drivers behind the quarterly figures previously reported.

Cohance Lifesciences has received a US FDA Form 483 with five observations pertaining to its Hyderabad facility. The issuance follows a regulatory inspection conducted by the United States Food and Drug Administration at the said manufacturing site.

US FDA Form 483: Key Details

A Form 483 is an official document issued by the US FDA at the conclusion of an inspection, listing observations where the agency's investigators believe conditions or practices at the inspected facility may constitute violations of the Food Drug and Cosmetic Act and related regulations. The following details have been reported in connection with this development:

Regulatory Context

The receipt of a Form 483 does not automatically imply a finding of non-compliance or regulatory action. Companies are typically given an opportunity to respond to the observations raised by the FDA investigators, outlining corrective and preventive actions. The nature and specifics of the five observations issued to Cohance Lifesciences' Hyderabad facility have not been detailed in the available information at this time.